.png){kind=icon}
返回
Y
You Lü
sichuan university
51H指数
431论文数
1.2W被引数
收录论文 151
发表时间
.png){kind=icon}
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study达可替尼作为亚洲表皮生长因子受体（EGFR）突变阳性局部晚期或转移性非小细胞肺癌患者的一线疗法：ARIA研究的最终分析.png)
Lung Cancer.png)
Lung CancerIF4.4
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏
Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor–Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations在一名对酪氨酸激酶抑制剂耐药的ALK阳性非小细胞肺癌伴中枢神经系统转移患者中，接受洛拉替尼治疗后实现成功妊娠和健康婴儿结局，并分析其母胎药代动力学及儿童发育里程碑的相关性。
OAAI
OAAI分享收藏AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)CANCER RESEARCH
CANCER RESEARCHIF16.6
PREAI
分享收藏